Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human neuroblastoma through a CD46 and nectin 4-independent pathway

Cancer Letters

Volumn 325, Issue 2, 2012, Pages 227-237

  Zhang, Shu Cheng ^a   Cai, Wei Song ^a   Zhang, Yao ^a   Jiang, Kai Lei ^a   Zhang, Ke Ren ^a   Wang, Wei Lin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

CD46; Measles virus Edmonston strain; Nectin 4; Neuroblastoma; Oncolytic

Indexed keywords

GLYCOPROTEIN; LYMPHOCYTE ANTIGEN; MEMBRANE COFACTOR PROTEIN; NECTIN 4; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIGENS, CD46; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHILD, PRESCHOOL; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; FIBROBLASTS; GENETIC VECTORS; GIANT CELLS; HUMANS; MALE; MEASLES VIRUS; MICE; MICE, NUDE; MICE, SCID; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; RECEPTORS, VIRUS; TUMOR STEM CELL ASSAY; VIRAL TROPISM; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS; MURINAE;

EID: 84865642785     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.008     Document Type: Article

References (58)

1. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
2. Maris J.M. Recent advances in neuroblastoma. New Engl. J. Med. 2010, 362:2202-2211.
3. National cancer institute. Surveillance, Epidemiology and End Results Database. (accessed November, 2005). http://seer.cancer.gov.
4. Modak S., Cheung N.K. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat. Rev. 2010, 36:307-317.
5. Soto B.L., Hank J.A., Van De Voort T.J., Subramanian L., Polans A.S., Rakhmilevich A.L., et al. The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol. Immunother. 2011, 60:731-738.
6. Ramírez M., García-Castro J., Alemany R. Oncolytic virotherapy for neuroblastoma. Discov. Med. 2010, 10:387-393.
7. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. New Engl. J. Med. 1999, 341:1165-1173.
8. Liu T.C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 2007, 4:101-117.
9. Peng K.W., TenEyck C.J., Galanis E., Kalli K.R., Hartmann L.C., Russell S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002, 62:4656-4662.
10. Heinzerling L., Künzi V., Oberholzer P.A., Kündig T., Naim H., Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005, 106:2287-2294.
11. Vidal L., Pandha H.S., Yap T.A., White C.L., Twigger K., Vile R.G., et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin. Cancer Res. 2008, 14:7127-7137.
12. Haralambieva I., Iankov I., Hasegawa K., Harvey M., Russell S.J., Peng K.W. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol. Ther. 2007, 15:588-597.
13. Gauvrit A., Brandler S., Sapede-Peroz C., Boisgerault N., Tangy F., Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specifc CD8 response. Cancer Res. 2008, 68:4882-4892.
14. McDonald C.J., Erlichman C., Ingle J.N., Rosales G.A., Allen C., Greiner S.M., et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 2006, 99:177-184.
15. Blechacz B., Splinter P.L., Greiner S., Myers R., Peng K.W., Federspiel M.J., et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006, 44:1465-1477.
16. García-Castro J., Alemany R., Cascalló M., Martínez-Quintanilla J., Arriero Mdel M., Lassaletta A., et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 2010, 17:476-483.
17. Pesonen S., Helin H., Nokisalmi P., Escutenaire S., Ribacka C., Sarkioja M., et al. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 2010, 49:117-119.
18. Li H., Dutuor A., Tao L., Fu X., Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin. Cancer Res. 2007, 13:316-322.
19. Parikh N.S., Currier M.A., Mahller Y.Y., Adams L.C., Di Pasquale B., Collins M.H., et al. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr. Blood Cancer. 2005, 44:469-478.
20. Elankumaran S., Rockemann D., Samal S.K. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 2006, 80:7522-7534.
21. Lacroix J., Leuchs B., Li J., Hristov G., Deubzer H.E., Kulozik A.E., et al. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int. J. Cancer 2010, 127:1230-1239.
22. Toyoda H., Yin J., Mueller S., Wimmer E., Cello J. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 2007, 67:2857-2864.
23. Dingli D., Peng K.W., Harvey M.E., Greipp P.R., O'Connor M.K., Cattaneo R., et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103:1641-1646.
24. Peng K.W., Ahmann G.J., Pham L., Greipp P.R., Cattaneo R., Russell S.J. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001, 98:2002-2007.
25. Meng X., Nakamura T., Okazaki T., Inoue H., Takahashi A., Miyamoto S., et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol. Ther. 2010, 18:544-551.
26. Phuong L.K., Allen C., Peng K.W., Giannini C., Greiner S., TenEyck C.J., et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003, 63:2462-2469.
27. Grote D., Russell S.J., Cornu T.I., Cattaneo R., Vile R., Poland G.A., et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001, 97:3746-3754.
28. Higuchi H., Bronk S.F., Bateman A., Harrington K., Vile R.G., Gores G.J. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res. 2000, 60:6396-6402.
29. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000, 406:893-897.
30. Anderson B.D., Nakamura T., Russell S.J., Peng K.W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004, 64:4919-4926.
31. Dhiman N., Jacobson R.M., Poland G.A. Measles virus receptors: SLAM and CD46. Rev. Med. Virol. 2004, 14:217-229.
32. Russell S. CD46: A complement regulator and pathogen receptor that mediates links between innate and acquired immune function. Tissue Antigens. 2004, 64:111-118.
33. RS Noyce, DG Bondre, Ha M.N., LT Lin, G Sisson, Tsao M.S., et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011, 7:e1002240.
34. Mühlebach M.D., Mateo M., Sinn P.L., Prüfer S., Uhlig K.M., Leonard V.H., et al. Adherens junction protein nectin 4 is the epithelial receptor for measles virus. Nature 2011, 480:530-533.
35. Sato H., Yoneda M., Honda T., Kai C. Morbillivirus receptors and tropism: multiple pathways for infection. Front Microbiol. 2012, 3:75.
36. Terao-Muto Y., Yoneda M., Seki T., Watanabe A., Tsukiyama-Kohara K., Fujita K., Kai C. Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines. Antiviral Res. 2008, 80:370-376.
37. Measles Virus, in Fields Virology. fifth ed. 2007, Lippincott Williams & Wilkins, Philadelphia. D.E. Griffin, D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
38. Peng K.W., Facteau S., Wegman T., O'Kane D., Russell S.J. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. 2002, 8:527-531.
39. Dingli D., Russell S.J., Morris J.C. In vivo imaging and tumor therapy with the sodium iodide symporter. J. Cell. Biochem. 2003, 90:1079-1086.
40. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., Dotsch C., et al. Rescue of measles viruses from cloned DNA. EMBO J. 1995, 14:5773-5784.
41. Parks C.L., Lerch R.A., Walpita P., Wang H.P., Sidhu M.S., Udem S.A. Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J. Virol. 2001, 75:910-920.
42. Lawrence D.M., Patterson C.E., Gales T.L., D'Orazio J.L., Vaughn M.M., Rall G.F. Measles virus spread between neurons requires cell contact but not CD46 expression, syncytium formation, or extracellular virus production. J. Virol. 2000, 74:1908-1918.
43. McQuaid S., Campbell S., Wallace I.J., Kirk J., Cosby S.L. Measles virus infection and replication in undifferentiated and differentiated human neuronal cells in culture. J. Virol. 1998, 72:5245-5250.
44. Duprex W.P., McQuaid S., Roscic-Mrkic B., Cattaneo R., McCallister C., Rima B.K. In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J. Virol. 2000, 74:7972-7979.
45. Watanabe A., Yoneda M., Ikeda F., Terao-Muto Y., Sato H., Kai C. CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J. Virol. 2010, 84:4183-4193.
46. Peng K.W., Frenzke M., Myers R., Soeffker D., Harvey M., Greiner S., et al. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. HumGene Ther. 2003, 14:1565-1577.
47. Wolman S.R., Camuto P.M., Perle M.A. Cytogenetic diversity in primaryhuman tumors. J. Cell. Biochem. 1988, 36:147-156.
48. Faivre J., Clerc J., Gerolami R., Herve J., Longuet M., Liu B., et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in Wistar rats. Cancer Res. 2004, 64:8045-8051.
49. Peng W., Henderson G., Inman M., BenMohamed L., Perng G.C., Wechsler S.L., Jones C. The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal Ganglia of acutely infected mice. J. Virol. 2005, 79:6162-6171.
50. Honda K., Takaoka A., Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360.
51. Fang Y.Y., Song Z.M., Dhib-Jalbut S. Mechanism of measles virus failure to activate NF-kappaB in neuronal cells. J. Neurovirol. 2001, 7:25-34.
52. Dhib-Jalbut S., Xia J., Rangaviggula H., Fang Y.Y., Lee T. Failure of measles virus to activate nuclear factor-kappa B in neuronal cells: implications on the immune response to viral infections in the central nervous system. J. Immunol. 1999, 162:4024-4029.
53. Servet-Delprat C., Vidalain P.O., Azocar O., Le Deist F., Fischer A., Rabourdin-Combe C. Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus. J. Virol. 2000, 74:4387-4393.
54. Toth A.M., Devaux P., Cattaneo R., Samuel C.E. Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J. Virol. 2009, 83:961-968.
55. Esolen L.M., Park S.W., Hardwick J.M., Griffin D.E. Apoptosis as a cause of death in measles virus-infected cells. J. Virol. 1995, 69:3955-3958.
56. Grote D., Russell S.J., Cornu T.I., Cattaneo R., Vile R., Poland G.A., et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001, 97:3746-3754.
57. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282:1332-1334.
58. Nemunaitis J., Ganly I., Khuri F., Arseneau J., Kuhn J., McCarty T., et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000, 60:6359-6366.